These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 16411141

  • 1. Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma.
    Yoshida K, Tomita Y, Okuda Y, Yamamoto S, Enomoto H, Uyama H, Ito H, Hoshida Y, Aozasa K, Nagano H, Sakon M, Kawase I, Monden M, Nakamura H.
    Ann Surg Oncol; 2006 Feb; 13(2):159-67. PubMed ID: 16411141
    [Abstract] [Full Text] [Related]

  • 2. Expression of hepatoma-derived growth factor in hepatocellular carcinoma.
    Hu TH, Huang CC, Liu LF, Lin PR, Liu SY, Chang HW, Changchien CS, Lee CM, Chuang JH, Tai MH.
    Cancer; 2003 Oct 01; 98(7):1444-56. PubMed ID: 14508832
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer.
    Ren H, Tang X, Lee JJ, Feng L, Everett AD, Hong WK, Khuri FR, Mao L.
    J Clin Oncol; 2004 Aug 15; 22(16):3230-7. PubMed ID: 15310766
    [Abstract] [Full Text] [Related]

  • 5. Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma.
    Yamamoto S, Tomita Y, Hoshida Y, Morii E, Yasuda T, Doki Y, Aozasa K, Uyama H, Nakamura H, Monden M.
    Ann Surg Oncol; 2007 Jul 15; 14(7):2141-9. PubMed ID: 17473954
    [Abstract] [Full Text] [Related]

  • 6. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer.
    Iwasaki T, Nakagawa K, Nakamura H, Takada Y, Matsui K, Kawahara K.
    Oncol Rep; 2005 Jun 15; 13(6):1075-80. PubMed ID: 15870924
    [Abstract] [Full Text] [Related]

  • 7. The expression and prognostic role of hepatoma-derived growth factor in colorectal stromal tumors.
    Hu TH, Lin JW, Chen HH, Liu LF, Chuah SK, Tai MH.
    Dis Colon Rectum; 2009 Feb 15; 52(2):319-26. PubMed ID: 19279430
    [Abstract] [Full Text] [Related]

  • 8. Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis.
    Fujii T, Nomoto S, Koshikawa K, Yatabe Y, Teshigawara O, Mori T, Inoue S, Takeda S, Nakao A.
    Hepatology; 2006 Jun 15; 43(6):1267-75. PubMed ID: 16628605
    [Abstract] [Full Text] [Related]

  • 9. Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer.
    Uyama H, Tomita Y, Nakamura H, Nakamori S, Zhang B, Hoshida Y, Enomoto H, Okuda Y, Sakon M, Aozasa K, Kawase I, Hayashi N, Monden M.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6043-8. PubMed ID: 17062679
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma.
    Nagaoka S, Yatsuhashi H, Hamada H, Yano K, Matsumoto T, Daikoku M, Arisawa K, Ishibashi H, Koga M, Sata M, Yano M.
    Cancer; 2003 Dec 15; 98(12):2671-7. PubMed ID: 14669288
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Serum C-reactive protein levels predict survival in hepatocellular carcinoma.
    Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Torimura T, Adachi H, Kurogi J, Tajiri N, Inoue K, Niizeki T, Koga H, Imaizumi T, Kojiro M, Sata M.
    Liver Int; 2007 Oct 15; 27(8):1091-7. PubMed ID: 17845537
    [Abstract] [Full Text] [Related]

  • 16. Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma.
    Zhang Q, Zhou J, Ku XM, Chen XG, Zhang L, Xu J, Chen GS, Li Q, Qian F, Tian R, Wen N, Chen ZN.
    Eur J Cancer Prev; 2007 Jun 15; 16(3):196-202. PubMed ID: 17415090
    [Abstract] [Full Text] [Related]

  • 17. Fascin expression in progression and prognosis of hepatocellular carcinoma.
    Iguchi T, Aishima S, Umeda K, Sanefuji K, Fujita N, Sugimachi K, Gion T, Taketomi A, Maehara Y, Tsuneyoshi M.
    J Surg Oncol; 2009 Dec 01; 100(7):575-9. PubMed ID: 19697358
    [Abstract] [Full Text] [Related]

  • 18. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma.
    Dong ZZ, Yao DF, Yao M, Qiu LW, Zong L, Wu W, Wu XH, Yao DB, Meng XY.
    Hepatobiliary Pancreat Dis Int; 2008 Jun 01; 7(3):288-95. PubMed ID: 18522884
    [Abstract] [Full Text] [Related]

  • 19. Receptor activator of nuclear factor-kappaB ligand (RANKL) expression in hepatocellular carcinoma with bone metastasis.
    Sasaki A, Ishikawa K, Haraguchi N, Inoue H, Ishio T, Shibata K, Ohta M, Kitano S, Mori M.
    Ann Surg Oncol; 2007 Mar 01; 14(3):1191-9. PubMed ID: 17195907
    [Abstract] [Full Text] [Related]

  • 20. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection.
    Yang XR, Xu Y, Shi GM, Fan J, Zhou J, Ji Y, Sun HC, Qiu SJ, Yu B, Gao Q, He YZ, Qin WZ, Chen RX, Yang GH, Wu B, Lu Q, Wu ZQ, Tang ZY.
    Clin Cancer Res; 2008 Jun 15; 14(12):3850-9. PubMed ID: 18559605
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.